I don’t usually do this – republish someone else’s complete blog post. I try to pull out the parts I want to say something about or emphasize, then link the source in case you want to read the whole thing. But I could find nothing I wanted to take out of this post by Dr. […]
GSK statement of support for AllTrials campaign for clinical data transparency AllTrials Feb 6, 2013 We are pleased to sign up to the AllTrials campaign for clinical trial transparency and support its call for the registration of clinical trials and the disclosure of clinical trial results and clinical study reports. At GSK, we are committed […]
Awakening into consciousness in the post-WWII era, I was unaware how fortunate I was. There was a large radio in the living room for endless entertainment. And some nights, it was announced we were going to the movies – and we went. Some families planned such things in advance, but we just went. Unless it […]
The flooding of the literature with industry sponsored articles whose primary function was advertisement is well known to most of us. GlaxoSithKline’s Paxil studies authored by Scientific Therapeutic Information [Sally Laden] and Janssen’s series of Risperdal articles managed by Excerpta Medica come immediately to mind [Rothman Report]. In the complaint in a recent suit filed […]
Clinical Trials of various sorts are intended to be the final word in evaluating both the safety and the efficacy of medications. In psychiatry, they’re more complicated because the outcome parameters are from the subjective reporting of either observers or subjects converted to objective data by rating forms and checklists. Unfortunately, they’ve moved to center […]
A Tough Push For Clinical Trial Disclosure In Europe Pharmalot By Ed Silverman February 4th, 2013 As the debate over clinical trial transparency heats up, the lead legislator for the Environment, Public Health and Food Safety Committee in the European Parliament wants to toughen proposed legislation that is designed to bolster clinical trial practices and […]
Rebalancing academic psychiatry: why it needs to happen – and soon by Arthur Kleinman The British Journal of Psychiatry. 2012 201:421-422. Summary: Academic psychiatry is in trouble, becoming the narrowest of biological research approaches of decreasing relevance to clinical practice and global health. What is required is a rebalancing of the psychiatric academy to include […]
If you choose not to support the DSM-5, there’s nothing to it: American Psychiatric Association (APA) launches new pages for DSM-5 – DSM-5 to cost $199 DxRevisionWatch by Suzy Chapman January 29, 2013 Unless you’ve had your head stuck in a bucket this last three years, you’ll be aware that the next edition of the American Psychiatric […]
PharmaTimes head-to-head debate Whitehead vs Goldacre The Royal Institution, Albemarle Street, London 26 February, 2013 5.00pm onwards Does pharma put profits ahead of patients? Is the industry failing to live up to the legal and moral standards expected of it? Or do its criticisers continue to push historical examples of malpractice and fail to recognise […]
Overseas Clinical Trials: Compare and Contrast Association of Clinical Research Organizations Globalization White Paper This report analyzes the current state of global clinical research and the role that biopharmaceutical companies and their clinical research organization (CRO) partners play in ensuring that the dual goals of trial safety and quality are met. With the changing landscape […]